Pharmaceuticals, Biotechnology and Life Sciences
Apitope’s ATX-MS-1467 has reduced the number and volume of brain lesions with a promising safety profile, the company said about results of a test.
The partnerships and deals struck at CPhI Russia have helped establish Russia at the forefront of pharmerging markets and it is expected to reach a value of $31.2 billion by 2019.
Faron Pharmaceuticals has recruited first patient in the Phase II INFORAAA clinical trial of Traumakine for the treatment of Multi-Organ Failure (MOF) and mortality prevention of surgically operated Ruptured Abdominal Aorta Aneurysm (RAAA) patients.
Mereo BioPharma’s bone disease drug BPS-804 has been accepted to participate in the European Medicines Agency’s (EMA) Adaptive Pathways programme.
AstraZeneca has entered into an agreement with TerSera Therapeutics for the commercial rights to Zoladex (goserelin acetate implant) in the US and Canada, an injectable luteinising hormone-releasing hormone agonist, used to treat prostate cancer, breast cancer and certain benign gynaecological disorders.
London-listed healthcare company Arix Bioscience said on Friday it raised £100 million in its Initial Public Offering, with total market capitalisation at Admission to be £187 million.
AstraZeneca has announced positive results from its Phase III OLYMPIAD trial comparing Lynparza (olaparib) tablets (300mg twice daily) to physician’s choice of a standard of care chemotherapy in the treatment of patients with HER2-negative metastatic breast cancer harbouring germline BRCA1 or BRCA2 mutations.
Takeda and TiGenix have presented new data from the Phase 3 ADMIRE-CD clinical trial of treatment refractory complex perianal fistulas in patients with Crohn’s disease at the 12th Congress of the European Crohn’s and Colitis Organisation (ECCO).
On Thursday, STADA Arzneimittel AG confirmed that it has received another legally non-binding conditional expression of interest regarding a bid for the acquisition of up to 100 percent of the shares in the company at an indicative takeover price of €58.00 per share.
Swedish Orphan Biovitrum (Sobi) has elected to add a novel product candidate (rFIXFc-XTEN) for the potential treatment of haemophilia B to the company’s collaboration agreement with Bioverativ.